程序性细胞死亡蛋白1及程序性细胞死亡配体1抑制剂在晚期膀胱癌治疗中的研究进展  

Research progress of PD-1/PD-L1 inhibitors in the treatment of advanced bladder cancer

作　　者：苏佳豪 杨明乾 梁朝龙 王坚 Su Jiahao;Yang Mingqian;Liang Chaolong;Wang Jian(Department of Urology,Affiliated Hospital of Guangdong Medical University,Zhanjiang 524000)

机构地区：[1]广东医科大学附属医院泌尿外科,湛江524000

出　　处：《中国综合临床》2023年第5期394-400,共7页Clinical Medicine of China

摘　　要：膀胱癌是常见的泌尿系统恶性肿瘤之一,其中以尿路上皮癌为主。传统的治疗方式主要为手术切除和化疗,然而晚期患者的治疗效果不佳,预后较差。近年来,随着免疫检查点抑制剂的开发,带来了许多较传统疗法效果更佳的治疗选择方案。程序性细胞死亡蛋白1(programmed cell death protein 1,PD-1)及程序性细胞死亡配体1(programmed death ligand 1,PD-L1)抑制剂通过阻断PD-1与PD-L1结合以中止免疫系统的负性调节,从而增强机体免疫系统的抗肿瘤活性。现对目前常用于临床治疗局部晚期或转移性膀胱尿路上皮癌的PD-1/PD-L1抑制剂的疗效、安全性等进行综述。Bladder cancer is one of the most common malignant tumors of the urinary system,among which urothelial carcinoma is the main one.The traditional treatment methods are mainly surgical resection and chemotherapy,but the treatment effect of advanced patients is not good,and the prognosis is poor.In recent years,with the development of immune checkpoint inhibitors,there are many treatment options that are more effective than traditional therapies.Programmed cell death protein 1(PD-1)and programmed cell death ligand 1(PD-L1)inhibitors stop the negative regulation of the immune system by blocking the binding of PD-1 and PD-L1,thereby enhancing the anti-tumor activity of the body's immune system.This article mainly reviews the efficacy and safety of PD-1/PD-L1 inhibitors commonly used in the clinical treatment of locally advanced or metastatic urinary tract carcinoma of the bladder.

关 键 词：晚期膀胱癌 尿路上皮癌 免疫检查点抑制剂 程序性细胞死亡蛋白1 程序性细胞死亡配体1 

分 类 号：R737.14[医药卫生—肿瘤]